指南与共识消化道肿瘤放疗姑息放疗与转移瘤放疗物理与技术

胰腺癌放射治疗:ASTRO临床实践指南

Radiation Therapy for Pancreatic Cancer: An ASTRO Clinical Practice Guideline.
指南 / 共识 · Pract Radiat Oncol · 2026-08-11

美国放射肿瘤学会组建多学科工作组,基于系统文献综述与预设共识方法,针对胰腺癌放疗的4个关键问题制定循证推荐。推荐涵盖可切除、交界可切除、局部晚期、转移及症状性疾病中放疗的适应证、时机、剂量分割、靶区与计划实施技术。

要点

  • 所有胰腺癌患者推荐多学科评估与决策。
  • 非转移性可切除病变术前/术后条件推荐放疗;交界可切除术前推荐;局部晚期根治性推荐。
  • 术前放疗推荐常规或中等大分割;术后推荐常规分割。

核心结论

  • 该指南为胰腺癌放疗的适应证、时机、剂量分割、靶区与实施技术提供循证推荐,并指出未来研究需进一步细化放疗适应证、与其他治疗的序贯及对患者结局的影响。

研究设计与样本

  • 美国放射肿瘤学会召集多学科工作组,基于系统文献综述和预设共识方法,采用证据质量与推荐强度分级系统,回答4个关键问题。

主要发现

  • 推荐所有患者接受多学科评估与决策;非转移性可切除病变术前和术后条件推荐放疗;交界可切除术前推荐放疗;局部晚期根治性推荐放疗。
  • 术前放疗推荐常规分割或中等大分割;术后放疗推荐常规分割;根治性放疗中常规分割合适,新兴证据支持SBRT或中等大分割剂量递增。
  • 剂量递增SBRT推荐自适应放疗;术前、术后和根治性放疗推荐选择性覆盖高危解剖区域。
  • 局部复发未接受过放疗者推荐放疗,曾接受放疗者条件推荐;出血、疼痛和梗阻推荐姑息放疗。
  • 寡转移和寡进展胰腺癌条件推荐对转移灶及未接受过根治性局部治疗的原发灶放疗。

关键数值与推荐

  • 推荐条款:所有患者多学科评估与决策。
  • 推荐条款:非转移性可切除术前/术后条件推荐放疗;交界可切除术前推荐;局部晚期根治性推荐。
  • 推荐条款:术前常规或中等大分割;术后常规分割;根治性常规分割合适,SBRT或中等大分割剂量递增有新兴证据支持。
  • 推荐条款:剂量递增SBRT推荐自适应放疗;术前、术后和根治性放疗推荐选择性覆盖高危解剖区域。
  • 推荐条款:局部复发未放疗者推荐放疗、曾放疗者条件推荐;出血、疼痛、梗阻推荐姑息放疗;寡转移/寡进展条件推荐转移灶及未根治的原发灶放疗。

临床怎么用

  • 胰腺癌放疗决策应经多学科团队评估,按疾病分期和既往治疗史选择放疗时机与分割方案。
  • 术前放疗可选常规或中等大分割,术后选常规分割;根治性剂量递增SBRT应配合自适应放疗并选择性覆盖高危区域。
  • 局部复发、出血、疼痛、梗阻及寡转移/寡进展患者可按推荐分层考虑放疗。

局限性

  • 原文未报告具体证据等级、推荐强度分级、检索时间范围及纳入研究数量。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: This guideline provides evidence-based recommendations on the use of radiation therapy (RT) for the treatment of pancreatic cancer in a variety of clinical settings including patients with resectable, borderline resectable, locally advanced, metastatic, and symptomatic disease. METHODS: The American Society for Radiation Oncology convened a multidisciplinary task force to address 4 key questions: (1) indications for and timing of RT for patients with nonmetastatic pancreatic cancer; (2) appropriate RT dose-fractionation regimens and target volumes for nonmetastatic disease; (3) preferred RT planning and delivery techniques for nonmetastatic disease; and (4) indications for RT in the locally recurrent, metastatic, reirradiation, and palliative settings. Recommendations are based on a systematic literature review and were created using a predefined consensus-based methodology with a system for grading evidence quality and recommendation strength. RESULTS: Multidisciplinary evaluation and decision-making are recommended for all patients. For patients with nonmetastatic pancreatic cancer, RT is conditionally recommended in the preoperative and postoperative settings for resectable disease. RT is recommended preoperatively for borderline resectable disease and definitively in the locally advanced setting. For preoperative RT, conventional fractionation or moderate hypofractionation is recommended. For postoperative RT, conventional fractionation is recommended. In the definitive setting, conventional fractionation is appropriate although emerging evidence supports dose escalation using either stereotactic body radiation therapy or moderate hypofractionation. Adaptive RT is recommended for dose-escalated stereotactic body radiation therapy. Elective coverage of at-risk anatomic regions is recommended for preoperative, postoperative, and definitive RT. In the locally recurrent setting, RT is recommended for patients without prior RT and conditionally recommended for those who have previously received RT. Palliative RT is recommended for patients with bleeding, pain, and obstruction. For patients with oligometastatic and oligoprogressive pancreatic cancer, RT is conditionally recommended to metastatic lesions and the primary tumor if not previously treated with definitive local therapy. Target volumes, simulation and planning techniques, and treatment recommendations are provided. CONCLUSIONS: These evidence-based recommendations provide guidance on the optimal use of RT for pancreatic cancer. Ongoing and future studies should further refine RT indications, sequencing with other therapies, and impact on patient outcomes.

来源:Pract Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Chuong MD, Jethwa KR, Ludmir E, et al. Radiation Therapy for Pancreatic Cancer: An ASTRO Clinical Practice Guideline. Pract Radiat Oncol. 2026. PMID: 42580553. doi:10.1016/j.prro.2026.07.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。